Based on data from Ng et al.34, where CXCR4 redirected CD38 CAR-expressing NK cells presented an enhanced BM homing in myeloma-carrying mice or where the co-expression of CXCR1 and the NKG2D CAR on NK cells was used to improve their efficacy against solid tumors9, one could expect this to at least be additive. The gene discussed is CD38; the disease is plasma cell myeloma.